Information Provided By:
Fly News Breaks for October 1, 2019
BHVN
Oct 1, 2019 | 06:54 EDT
After hosting a key opinion leader call to discuss prospects for rimegepant to potentially change the landscape for migraine prevention, Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on Biohaven Pharmaceutical with an $87 price target. The analyst now has "enhanced conviction" on the Phase 3 readout in 2019 and believes rimegepant has the potential to disrupt the migraine treatment paradigm and open the door for oral anti-CGRP-based therapy to become the standard of care across the continuum in both acute and preventative settings.
News For BHVN From the Last 2 Days
There are no results for your query BHVN